Ann: Optiscan Imaging Acquires Intellectual Property, page-15

One thing for sure you need images if you are going to develop AI image interpreting software.
The images that become available to Optiscan from this deal are extensive and "confirmed clinical and histopathological
diagnoses are matched to images from the Company’s confocal platform." Also images from the use of two imaging agents
"fluorescein (in vivo use) and acriflavine (ex vivo use) as topical contrast agents for determination of cellular
microstructure, and diagnostic and surgical utilisation."
No reason Optiscan won`t develop their own AI image interpretation platform as Zeiss are currently doing.adding the commercial opportunity
from InVivage.